Update of novel agents in treating relapsed and refractory multiple myeloma / 白血病·淋巴瘤

ABSTRACT

The treatment of relapsed and refractory multiple myeloma has always been a problem among hematologic malignant tumor treatment.Compared with the initial therapy,there are worse therapeutic effects and more affecting factors of selecting treatment since the existence of drug resistance in relapsed myeloma.In this review,the therapeutic effects of single and combinational use of several novel agents such as thalidomide,lenalidomide and bortezomib were evaluated in treating relapsed and refractory multiple myeloma.The clinical results of some new anti-myeloma agents were also reported.